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Abstract 
Rare diseases (RDs) are a global priority yet are still under researched. When combined, RDs are 
common, with individual diseases numbering approximately 5,000-8,000, equating to approximately 
7% of the population in Europe. Extrapolating this figure for Australia suggests that about 1.2 million 
people are affected by RDs, with about 400,000 of those being children. The WA Rare Diseases 
Strategic Framework 2015-2018, the first strategy for rare diseases in Australia, recognises that in 
order to alleviate the significant burden of rare diseases, innovative translational tools that facilitate 
research into new diagnostic and therapeutic strategies should be given priority.  
Registries facilitate clinical, epidemiological, and post-marketing surveillance research for RD, 
collecting information from individuals with a particular disease, and storing these data in an 
organised system. Registries can lead to a greater understanding of the natural history of disease, 
consensus-driven treatment protocols, informed policy making and, in turn, improved patient 
outcomes. Despite these benefits, registries are limited in their capacity to conduct basic research, 
attributed to the fact that most registries do not collect and store patient and donor specimens 
appropriately to capture or preserve important biological information (such as DNA, RNA and 
proteins) for basic research, a prerequisite for translating scientific discoveries into diagnostic tools 
and therapies for clinical practice.  
Biobanks (BB) are gradually becoming more recognised as invaluable tools to drive basic and 
translational research for RDs. BBs collect and store biological specimens with matched clinical data 
and patient metadata in an organised system, distributing samples and data to the scientific 
community, enabling “omics” studies. This is especially important considering the field of drug 
innovation for RDs has, in recent years, become progressively focused on ‘omics-type research, and 
that more than 80% of RDs have a genetic component RDs have recently been referred to as 
“fundamental diseases”, highlighting their unique capacity in providing opportunities to investigate 
the “extremes of human pathology”. For example, research of LDL-receptors in familial 
hypercholesterolemia, a rare disease, led to the discovery of statins, a drug therapy that is now also 
routinely used to prevent heart disease.  
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This Masters research thesis examined the research outcomes of two specific research strategies: 
registries linked to BBs and registries without BBs, and found that whilst registries without BBs had 
the capacity to uncover the natural history of disease, develop best practice, replace clinical trials, 
and improve patient outcomes, they were limited in their capacity to conduct basic research. 
Registries, when annexed to BBs, had the key infrastructure required to make novel Omics 
discoveries, identify and validate biomarkers, uncover novel genes, and develop new therapeutic 
strategies. The results of this Masters research thesis suggest that the role of basic research in RD 
research is vital; scientists must first understand the pathways of disease before they can develop 
appropriate interventions. Linkage of BBs to RD registries will provide the enhanced resources 
required for the effective translation of basic research into clinical practice. 
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1.  Introduction – Rare Diseases, Registries, and Biobanks 
1.1  Rare Diseases  
Rare diseases (RDs), also known as “orphan” or “neglected” diseases, each occur in small 
percentages of the population. The European Union (EU) consumer- endorsed definition of RDs is 
diseases with “life-threatening or chronically debilitating diseases which are of such low prevalence 
(1 in 2,000 people) that special combined efforts are needed to address them” (European 
Commission, 2013). “RDs are variant phenotypes created by the experiment of nature and 
misfortunes of the environment” – Professor Wei Wang. The phenomes can be defined at any level 
of biological systems: molecules, organelles, cells, tissues, or organs. Paradoxically when combined, 
RDs are common, with individual diseases numbering approximately 6,000-8,000, and those affected 
equating to around 7% of the population, or 30 million people in Europe (European Commission, 
2013). Extrapolating this figure for Australia suggests approximately 1.4 million people are affected 
by RDs (Department of Health, Australia, 2015). RDs occur across 27 disease categories, with 
newborns and children the most frequently affected (Lacaze et al, 2017). Approximately 80% of all 
RD have a genetic component, are often disabling, incurable, painful, and cause great suffering (Jaffe 
et al, 2010). Very few RD have effective treatments. These factors make the diagnosis, management, 
and treatment of RD patients inherently challenging. This has a significant impact on patients, 
clinicians and the health system.  
Diagnosis of RD 
The impact of receiving a RD diagnosis is often a devastating experience for families (Zurynski et al, 
2017). For RD patients, diagnosis is often delayed, attributable to a lack of available information and 
knowledge by treating clinicians (Jaffe et al, 2010). Moreover, misdiagnosis of the disease is not 
uncommon (Zurynski et al, 2017). A recent study surveyed 462 families who had a child with a RD 
under the age of 19. The results highlighted the consequences of a delayed diagnosis for families, 
which included the need to consult multiple clinicians in order to find answers for their children 
(Zurynski et al, 2017).  The research found 41% of families consulted three to five doctors, 16% 
consulted six to ten doctors, and 11% consulted over ten doctors (Zurynski et al, 2017). The study 
also showed that 8% of children did not receive a diagnosis for over 3 years. Frustration, anxiety, 
progression of disease, and delayed treatment have been reported by parents as common yet 
serious consequences resulting from a delayed diagnosis (Zurynski et al, 2017). The most common 
perceived reason for a delayed diagnosis by parents is lack of knowledge of RD by health care 
professionals (Zurynski et al, 2017).  
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Management of RD 
RD are complex to manage and often require a multidisciplinary team of healthcare providers (Elliot 
& Zurynski, 2015).  It has been recognised that General Practitioners (GP) play a crucial role in the 
overall management of RD (Elliot & Zurynski, 2015). Research shows that approximately 80% of all 
children with RD visited their GPs more than once in the prior 12 months (Elliot & Zurynski, 2015). 
The role of GPs may include case coordination, care plans, and specialist referrals. Indeed, GPs can 
assist in accelerating the process of an earlier diagnosis by referring their patients to specialist’s 
sooner (Elliot & Zurynski, 2015).  
Treatment of RD 
For RDs, it is not uncommon for inappropriate and inefficacious treatments to be used (Zurynski et 
al, 2017). Obtaining a correct diagnosis may be of little value to the patient, as very few RDs have 
available or effective treatments (Lacaze et al, 2017). Indeed, until recently, there has been a 
reluctance from pharmaceutical companies to show interest in developing therapies for RD, as the 
market is so small (Elliot & Zurynski, 2015).  
Impact of RD 
It is known that families are severely affected by the negative consequences of RDs, and have been 
referred to as a “medical disenfranchised population that falls through the cracks of every 
healthcare system in the world” (Myers et al, 2003). Healthcare systems themselves, however, are 
also significantly impacted by RD. For example, in Western Australia (WA), a recent data linkage 
study found 467 rare diseases were logged in hospital records, accounting for 2% of the WA 
population (Walker et al, 2016). The study also showed approximately 10% of all hospital admissions 
in WA were related to rare diseases. Moreover, RDs accounted for 10.5% of total WA hospital 
expenditure ($395 million) over one year (Walker et al, 2016). Despite the very large number of RDs 
in existence, there are only approximately 400 drugs approved worldwide (Kakkis et al, 2015). As a 
result, RDs place a significant burden on the healthcare system, with greater dependency on hospital 
resources being observed in this cohort (Department of Health, Australia, 2015). This demonstrates 
marked disparity between the RD population and the total cost to the state health system, 
underscoring the substantial financial burden RDs place on society.  
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It has been recognised that to alleviate the burden of RDs, substantial research into new diagnostic 
and therapeutic strategies are needed. In response, the WA Rare Diseases Strategic Framework 
2015-2018 developed the first strategy for RDs in Australia. Among its many objectives, the 
framework strives to improve the health and wellbeing of those affected by RD through the 
advancement of RD planning in Australia, and by fostering world class clinical and translational 
research. The framework highlighted the importance of developing registries in RD research 
(Department of Health, Australia, 2015). More recently, Rare Voices Australia (RVA) created a public 
Communique, calling for a national plan for RD registries to be developed (Lacaze et al, 2017).  
RDs pose challenges not only for health systems but also for research activities. Researchers are 
faced with limited samples numbers that are scattered geographically, disease classifications which 
are often unclear, and a general lack of interest and funding in RD. As a result of these deficiencies, 
RDs have become priority areas for many public health programs throughout the world (the National 
Organization for Rare Disorders (NORD), European Organisation for Rare Diseases (EURORDIS), WA 
Health Department). Data collection, such as clinical data, is crucial in the field of RD as without 
collecting this basic data, improving the management of the disease or furthering research will not 
be possible (Lacaze et al, 2017). Orphanet, an online catalogue of over 6,000 RDs and directory of 
expert resources for participating countries, recently stated that registries are “the only way to pool 
data in order to achieve a sufficient sample size for epidemiological and/or clinical research” 
(Orphanet, 2016). 
1.1.2 Registries 
 
Registries are information systems that collects data from patients. The type of information 
collected is dependent on the registries aims, objectives, and scope. A registry may be specific to a 
disease, population, or an intervention. Data collection for RD is not dissimilar to that of common 
disease registries. RD registries seek to collect a uniform set of data for each patient (Glickich et al, 
2014). Registries can enable epidemiological research, post-marketing drug surveillance, and assist 
in health service delivery planning (Lacaze et al, 2017). In addition to collecting clinical data, RD 
registries should aim to collect information that offers meaning to both patients and clinicians 
regarding quality of life (Lacaze et al, 2017). Ultimately, a RD registry aims to improve patient 
outcomes. Unfortunately, in Australia, the true incidence and prevalence for RD are unknown 
(Lacaze et al, 2017). This can be attributed, in part, to a lack of RD registries to collect clinical patient 
information (Lacaze et al, 2017). National and international registries for RDs are often required as 
the patient numbers in local jurisdictions for each RD are too few. Thus, they bring together patients 
to facilitate research (Department of Health, Australia, 2015). One successful Australian registry, for 
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example, the Australian Rett Syndrome Database, established in 1993 to investigate the rare 
neurodevelopmental disorder, has led to a greater understanding of the natural history of disease, 
impact of treatment, and facilitated more than 100 research publications on Rett syndrome (Downs 
and Leonard, 2016).  
 
1.1.3  Biobanks 
As well as clinical data, some RD registries also collect biological samples such as blood. Samples are 
processed and stored in specialised freezers in universities or institutes set up as a Biobank (BB). 
Biobanks, also referred to as “biological specimen banks”, “tissue banks” or “biorepositories”, link a 
patient’s biological sample to their clinical data, providing detailed phenotypic and genotypic 
information. The aim of a BB is to then make samples and data available to the scientific community 
for further studies. The United Kingdom BB is one of the world’s largest BBs with over 500,000 
participants aged between 40-69 years (Elliot & Peakman, 2008). The open-access resource enables 
investigations of genetic and environmental cause of diseases to improve the prevention, diagnosis, 
and treatment of diseases affecting the greater community (Sudlow et al, 2015).  
Recently, research into RDs has been shown to have a significant impact in the acceleration of drug 
discoveries (Pariser & Gahl, 2014). As a result, RDs have been referred to as “fundamental diseases”, 
providing opportunities to investigate the “extremes of human pathology” whilst also affording 
unique insights into normal and abnormal human physiology (Pariser & Gahl, 2014; Hall & Sireau, 
2014). This leads to a greater understanding of biological pathways and the identification of 
therapeutic strategies not only for RDs, but also common diseases (Monaco et al, 2015). For 
example, research of low-density lipoprotein (LDL)-receptors in familial hypercholesterolemia, a RD, 
led to the discovery of statins, a drug therapy that is now routinely used to prevent heart disease 
(Hall & Sireau, 2014).  
Whilst BBs require significant commitment, planning and long-term funding, the benefits of drug 
discovery far outweigh the costs (Li et al, 2016). Indeed, their true value is not reflected in the cost 
of associated infrastructure, such as freezers. Rather, a BBs true value is found in the information 
they capture and provide. This is especially so with RDs, where “every sample counts” (Zhou & 
Catchpoole, 2009).   
BB’s are becoming an increasingly important resource for rare disease research. Biobanks are 
established with 6 key principles in mind – resources, appropriateness, sustainability, privacy, 
confidentiality and trust. Biobanks aim to provide a resource for research purposes that is valued by 
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society. Biobanks aim to ensure their procedures (collection, transport, storage, access, use, and 
disposal) involving participants’ samples are data are appropriate from a scientific, legal, and ethical 
standpoint. It is prudent the custodian of the biobank develops a business plan to secure 
sustainability of the biobank. Participant’s privacy is considered paramount in any biobank, with data 
remaining confidential. Biobanks need to operate in a transparent and respectful manner, gaining 
the trust and ongoing involvement of the public.  
 
Three main categories of biobanks exist, including disease-specific, population, and pathology 
biobanks (Graham et al, 2014). Disease-specific biobanks (e.g. the International Early Onset Scoliosis 
Biobank) refers to bio specimens collected for a specific phenotype or group of phenotypes (Olson, 
2014), and are commonly used for RD (Graham et al, 2014).  New technologies, such as next 
generation sequencing, have enabled research (derived from samples stored in biobanks) to identify 
new genes, gene mutations, biomarkers, understand genotype-phenotype correlations, and uncover 
aetiologies of RD (Graham et al, 2014). BB’s also facilitate precision medicine, a new classification of 
medicine designed to personalise treatments through targeted therapy.  
 
1.3  Overview, specific aims and hypotheses 
 
Area of research strength 
This Master’s thesis research aligns with the Australian government’s research priority of Promoting 
Population Health and Well-being, the WA Rare Diseases Strategy 2014-2018, and Edith Cowan 
University’s (ECU’s) research area of Health and Wellness. 
 Aims 
Overall aim: This Master’s thesis research aimed to identify the impact of BBs and interventions 
derived from BB infrastructure on research outcomes in RDs, and compare research outcomes in 
RDs that are or are not associated with a BB infrastructure.  
Specific aims 
 To identify the impact of registries linked to biobanks on rare disease research outcomes 
 To compare the differences between registries with and without biobanks on research 
outcomes and to explore what factors give rise to these differences 
 To provide recommendations for practice and policy 
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Hypothesis 
Rare disease registries, when annexed to biobanks, accelerate rare disease research outcomes.   
Significance 
The lack of aetiological research for fundamental diseases have made them a priority area in many 
basic sciences, applied sciences and public health programs throughout the world (European 
Commission, 2018; Eurordis, 2018). The term rare disease has recently been coined “fundamental 
diseases” (Hall & Sireau, 2014) highlighting their importance and unique capability in discovering the 
cellular pathways of other conditions, including common diseases. Up until recently, fundamental 
diseases have been inherently difficult to study. Biobanks are becoming an increasingly important 
resource for fundamental disease research. With the advent of new “omics” technologies, 
fundamental disease biobanks may hold the key to new discoveries for rare diseases (Lochmuller et 
al, 2017). 
2. Methods 
2.1  Research Design 
A Systematic Review and Meta-aggregation was conducted using the preferred reporting items for 
systematic reviews and meta-analyses (the PRISMA statement) (Moher et al, 2009). The Joanna 
Briggs Institute Qualitative Assessment and Review Instrument (JBI-QARI) method of meta-
aggregation was used for critical appraisal of articles, data extraction, and synthesis of data (Hannes 
and Lockwood, 2011). This qualitative method was developed to mirror the Cochrane’s collaboration 
processes for quantitative systematic reviews.  
 
 2.1.1    Search Strategy 
All articles from 1991, to include the pre-genomic and genomic era, to the end of 2016 published in 
English were considered. This served to capture the establishment of biobanks in the early 2000s. 
PubMed, Medline, Scopus and Web of Science databases were utilised. The following search terms 
were used: Rare diseases OR neglected diseases OR orphan diseases AND Biological Specimen Bank 
OR tissue bank OR registries/standards* OR registries/therapies* OR biobank* OR biorepository (in 
Figure 1).  
 
2.1.2 Eligibility Criteria 
Original research papers that reported clinical, epidemiological, basic or translational research 
findings derived from data contained in a RD registry with or without a BB. All study designs were 
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included. Retrieved articles were initially screened by title and abstract, and if potentially eligible, 
their full-text was reviewed.  
 
2.1.3  Critical Appraisal  
Articles selected for inclusion were assessed using the critical appraisal instruments by JBI-QARI. Two 
researchers performed the critical appraisal and compared results. In the instance of a 
disagreement, a third party was sought, and consensus was reached. Recorded information for each 
article included: date of publication, title, authors, citation, and abstract for later review.  
 
 2.1.4  Data Extraction  
A comprehensive data extraction coding sheet was first developed and pilot-tested on 3 randomly-
selected included studies, and refined accordingly. Four domains were developed for the coding 
sheet – study quality, methodology, type of intervention, and data/specimen collection fields. Each 
article was read in its entirety and findings were extracted using the online data extraction software 
by the JBI-QARI. Findings were recorded as verbatim quotes of the author’s interpretation of results. 
An illustration (direct quote) was included to support each finding. Findings were assigned a level of 
plausibility (unequivocal or credible).  
 
 2.1.5  Data Synthesis 
Data was synthesised using meta-aggregation analysis (Lockwood et al, 2015).  The findings were 
grouped through similarity of meaning. Categories were developed to describe the concepts of each 
group of findings, with at least two findings per category. The categories were then grouped into a 
synthesised finding with at least two categories per synthesis. Categories were then grouped into six 
themes: basic science, translational science, clinical observation, clinical treatment, study quality, 
and facilitators and barriers. The synthesised findings constituted the set of recommendations for 
practice and policy. The search retrieved 432 citations; 311 were excluded, with full text retrieved 
for 109. Of those, 79 did not meet the eligibility criteria. A total of 30 articles were included in the 
review (Figure 6). Ethics declaration was obtained at the completion of the review.  
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3        Results 
The search returned a total of 30 articles. There were 15 RD registries with a BB, and 11 RD registries 
without a BB. Of the 15 RD registries with a BB, 9 were international networks, 5 were national 
networks, and 1 was a single site initiative. Of the 11 RD registries without a BB, 6 were international 
networks, and 5 were national networks. The registries were European (n=12), International (n=7), 
North American (n=4), Australian and New Zealand (n=2), and Canadian (n=1). Twenty-one registries 
were established since 2000, with 9 established since 2010. Studies were mainly prospective and 
longitudinal in design, with only a few registries collecting retrospective or cross-sectional data. 
Disease categories included cancer, genetic, neuromuscular, neurological, lung diseases, 
cardiovascular, urogenital/renal, autoimmune, autoinflammatory, endocrine, blood and hereditary 
ocular diseases. 
 
Papers identified in PubMed, 
Medline, Scopus, and Web of 
Science databases (n= 432) 
Papers screened by title and 
abstract, duplicates removed 
(n= 121) Papers excluded (n= 311) 
 
Papers excluded after full-
text screening (n= 79) 
Papers included in qualitative 
synthesis (n=30) 
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Papers screened by full text  
(n= 109) 
Figure 1.  Flow diagram for article section and inclusion of review 
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3.1  Study Quality 
 
Registry cohorts ranged from paediatrics to adults or included both children and adults. Registry 
cohort sizes ranged from 23 to greater than 13,500 participants. The total number of biospecimens 
collected ranged from 46 to over 500,000. The number of research projects from RD registries and 
BBs ranged from 1 to 784, with the number of research publications ranging from 1 to 255 since the 
project started.  
 
Twenty registries listed their funding sources: four were funded by the European Commission; three 
were funded by pharmaceutical companies; two by each of the following including the Department 
of Health, foundations, institutes, and research trusts; and one from each of the following including 
a university, charity, society, and benefactor funds; and one from a variety of sources. Four registries 
reported funding amounts ($170K per annum, 1.22 M, 1.6M, unrestricted funding). Nineteen 
registries reported that their data and samples are available to researchers.  All 26 registries 
specified the RD name of interest, yet only five used the World Health Organisation (WHO) 
International Classification of Disease (ICD) or the Online Mendelian Inheritance in Man (OMIM) 
coding systems. A list of the registries, and their association with BBs at the time the original article 
was published, can be found in Tables 1 and 2.  
 
Table 1: List of rare disease registries and whether or not they are associated with a biobank 
Study 
ID 
Author Title Registry 
with 
Biobank 
Registry 
only 
Themes 
associated 
with 
resource 
N1-
001 
O'Souji, C The Children's Oncology Rare and 
Cutaneous NHL registry 
2  CO, CT, B 
N1-
002 
Mora, M The Eurobiobank Network 2  BS, T, CT, F, 
B 
N1-
003 
Filacomo, M Telethon Network of Genetic 
Biobanks 
2  BS, T, CO, F, 
B 
N1-
004 
Ebner, K The European ARPKD registry 2  CO, CT, F 
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N1-
005 
Blain, D Eyegene 2  BS, CT, F 
N1-
006 
Bush, A European Management Platform 
for Childhood Interstitial Lung 
Diseases 
2  CT, F 
N1-
007 
Martin, N The UK JDM Cohort Biomarker 
Study and Repository Juvenile 
Dermatomyositis (UK and Ireland) 
Cohort Biomarker Study and 
Repository for Idiopathic 
Inflammatory Myopathies 
2  CO, CT, F, B 
N1-
008 
Fisher, C The PTS Registry and Biobank 
Network - an AOSpine Knowledge 
Forum Tumour Study 
2  BS, CO, CT, 
F, B 
N1-
009 
Ugolini,  The CREST Biorepository 1  F 
N1-
010 
Brandenburg, V The German Calciphylaxis Registry 1  BS, CO, CT, 
F, B 
N1-
011 
Struik, M The Dutch 
Lymphangioleiomyomatosis (LAM) 
Registry 
1  F 
N1-
012 
Squitieri, J Italian Huntington Disease 
Patients - Data and Tissue Bank 
1  F 
N1-
013 
Li, J Friedrich's Ataxia Fibroblast 
Repository 
1  F 
N1-
014 
Zhou, L The Tumour Bank at the Children's 
Hospital Westmead (TB-CHW) 
0  F 
N1-
015 
Bladen, C The TREAT-NMD Duchenne 
Muscular Dystrophy Registries 
 2 CT, B 
N1-
016 
Webb, S The European Registry of 
Cushing's Syndrome (ERCUSYN) 
Registry 
 2 CO, CT, F 
N1-
017 
Sharkey, E The NF1 Patient Registry Initiative   2 CO 
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N1-
018 
Rodger, S The TREAT-NMD Care and Trial 
Site Registry 
 2 BS, CO, F, B 
N1-
019 
Tilson, H The Cryopyrin-associated Periodic 
Syndrome (CAPS) Registry 
 2 T, CO, CT, F, 
B 
N1-
020 
Mistry, P The International Collaborative 
Gaucher Group (ICGG) Gaucher 
registry 
 2 CO, CT 
N1-
021 
Evangelista, T The UK Facioscapulohumeral 
Muscular Dystrophy Patient 
Registry 
 1 BS, CO, CT, 
F, B 
N1-
022 
Hilbert, J The National Registry of Myotonic 
Dystrophy (MD) and 
Facioscapulohumeral (FSHD) 
 1 BS, CO, F 
N1-
023 
Fasnacht, M The Swiss Registry for Pulmonary 
Arterial Hypertension 
 1 BS, CO, CT, 
F 
N1-
024 
Downs, J 
Leonard H, 
Louise, S 
The Australian Rett Syndrome 
Database  
The InterRett Database 
 
 1 
2 
CO, F 
N1-
025 
Korngut, L The Canadian Neuromuscular 
Disease Registry (CNDR) 
 1 F, B 
N1 - 
026 
Fehr, S The International CDKL5 Disorder 
Database 
 2 CO, F 
N1-
027 
Akbarnia, B The Growing Spine Study Group  2 CO, CT, F 
BS-Basic Science   T-Translational Science CO-Clinical Observation 
CT-Clinical Treatment F-Facilitators   B-Barriers 
0–Single site  1–National registry  2–International registry 
 
3.1.1  Increased Research Activity 
There is overwhelming evidence that RD registries significantly increase research projects, and this is 
amplified when it is a member of a network. Comparatively, RD registries with BBs generate 
quantifiably more research activity and publications than RD registries without BBs. For example, the 
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use of samples from a European BB network has been acknowledged in 255 publications from 2004-
2013 (Mora et al., 2015). An Italian network provided thousands of samples to national and 
international researchers over a 5-year period (Filocamo et al., 2013). This led to 784 research 
projects, with over 250 scientific publications from 2008-2012 (Filocamo et al., 2013). In this review, 
the articles analysed reported the number of research projects and enquiries totalled 898 for RD 
registries with BBs, compared to 172 for RD registries without BBs. This is a 5-fold increase in 
research projects utilising RD registries with BBs. Further, the articles analysed in this review 
reported research publications totalling 571 for RD registries with BBs, compared to 26 for RD 
registries without BBs. This is a 21-fold increase for RD registries with BBs (Figure 7).  
 
Figure 2. Research impact of RD registries with and without BB 
3.1.2  Synthesised Themes 
The synthesis generated 480 findings, 34 categories, and 6 themes. The themes were titled basic 
science, translational science, clinical observation, clinical treatment, study quality, and facilitators 
and barriers. An example of the meta-aggregation for this study is illustrated in Figure 3 and 4. 
 
 
 
Figure 3. Example of meta-aggregation. Direct quotes from an article is recorded verbatim as an 
illustration of the study, and then summarised into a finding 
     
Figure 3. Direct quotes are recorded verbatim, summarised into findings, and assigned into a 
category.  
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Illustration from study – Martin, N – Rheumatology (2011)  
The establishment of the JDRG has provided a forum for regular communication between members, and facilitated 
discussion regarding treatment approaches. There is emerging evidence that this had led to a gradual shift in practice 
from the initial cohort. Treatment for JDM is not yet evidence based but the group has facilitated emerging 
consensus. Standardizing treatment protocols are currently under discussion and will hopefully be adopted by the 
group, providing a more secure basis for assessing outcome and the basis of future therapeutic studies. P141 
Finding - This study has led to a shift in practice through achieving consensus and beginning the standardisation of 
treatment protocols. 
Category – Guidelines for treatment 
29 
 
           Finding    Category        Synthesised finding 
 
   
3.2  Basic Science 
 
 
 
 
 
 
 
 
 
  
 
Figure 4. Meta-aggregation example – Findings from study number 7, 15, 15, and 1 
 
3.2.1  Omics 
This review found that registries linked to BBs impacted on RD research outcomes by facilitating 
Omics studies and discoveries, leading to scientific advancement. No evidence of basic science 
research being conducted in registries without a BB was found. This can be attributed to the fact 
that registries without BBs do not collect biological samples; therefore, they lack the ability to 
conduct basic science investigations. Conversely, registries with BBs collect, and have access to, 
biological samples, such as blood for DNA and fibroblasts for cell lines. As a result, registries with BBs 
can conduct laboratory studies (such as investigating the aetiopathogenesis of disease). Basic 
science is the first step in the translational science process, with discoveries made in this stage 
having the potential for future development into new diagnostic tools and therapies, relevant for 
clinical practice.  
This study has led to a 
shift in practice 
through achieving 
consensus and 
beginning the 
standardisation of 
treatment protocols. 
Treatment 
evaluation 
Guidelines for 
treatment 
The registry has led to 
improvement in 
patient care 
The registries have 
allowed for critical 
analysis of current 
treatment protocols, 
such as the use of 
corticosteroids 
Treatments for rare 
NHL cancers are highly 
variable, ranging from 
observation or surgery 
alone to stem cell 
transplant 
Clinical treatment 
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The basic science discoveries included the characterisation of new syndromes, biomarker discovery 
and validation, elucidation of biological pathways involved in disease, molecular modelling of 
pathogenic variants, characterisation of epigenetic factors involved in disease expression, genotype-
phenotype correlations, molecular analysis of DNA methylation, chromatin structure, gene-
transfection and gene-silencing studies, studies involving growth factors and cytokines, identification 
of new gene and novel mutations, and exon-skipping (Mora et al., 2015; Blain, Goetz, Ayyagari, & 
Tumminia, 2013; Filocamo et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3. Translational Science 
3.3.1  Availability of Biospecimens for Research 
This review found that registries linked to BB impacted on RD research outcomes in translational 
science by contributing biological specimens to research projects, leading to new therapies to treat 
3.2.1.1  Case Example –Omics 
In 2011, utilising samples entirely from the Cancer of Respiratory Tract (CREST) biorepository that was 
primarily established to study mesothelioma (a rare and serious form of lung cancer), a study was conducted 
to evaluate new biomarkers for non-small cell lung cancer (NSCLC), the most common form of lung cancer 
(Foss et al, 2011). A large proportion of lung cancers (>75%) are detected in the later stages of the disease, 
attributable to a lack of appropriate screening tools for large numbers of people. Whilst computed 
topography (CT) screening has been used for at-risk individuals, it is not ideal. For example, approximately 
50% of tumours detected by CT are benign, and for every death prevented using this method, two invasive 
procedures resulting from false-positive results will occur. Late detection using current methods has resulted 
in poor prognoses for lung cancer patients. Conversely, early detection leads to improved patient outcomes. 
Therefore, the rationale for biomarker development in lung cancer was for earlier detection of NSCLC, which 
may lead to improved survival rates. The study aimed to identify serum-based biomarkers for NSCLC. Blood-
serum was obtained from 22 participants (11 with early-stage NSCLC and 11 controls) provided by the CREST 
biorepository. Using microRNA (miRNA) profiling on total RNA, the study found the expression of two miRNAs 
(has-miR-1254 and has-miR-574-5p) to be significantly elevated in NSCLC cases when compared to controls. 
Quantitative polymerase chain reaction (qPCR) validated the results, with the authors concluding the findings 
justified additional consideration and validation of these serum-based biomarkers for early-stage non-small 
cell lung cancer. The CREST biorepository demonstrates how RD BBs can impact on outcomes (biomarker 
development) in basic science, not only for RDs (mesothelioma), but also common disease (NSCLC). 
Moreover, the CREST biorepository stores blood samples over many years, and includes banked samples from 
individuals prior to their lung cancer diagnosis. This makes RD BBs invaluable for testing the applicability of 
NSCLC serum-based biomarkers, an opportunity not afforded to other biomarker studies.  
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RD. Registries without BB could not contribute biological specimens, and so lacked the capacity to 
contribute to the development of new diagnostic tools and therapies. The registries with BB in this 
review donated biological samples to pharmaceutical companies (such as Pfizer), consortiums, and 
international studies (Filacomo et al, 2013).  
3.3.2 Clinical Trials  
This review found that registries both with and without BBs impacted on RD research outcomes in 
clinical trials with regards to increased patient recruitment and novel safety monitoring approaches. 
It was found that RD registries can not only be used in place of randomised controlled trials (RCT), 
they are often more advantageous (Tilson et al, 2013). Unlike RCTs, registries are unrestricted in 
their cohort size, and have no dictated treatment regimens or strict inclusion criteria (Tilson et al., 
2013). Registries have the capacity to collect information from patients in a real world setting during 
routine clinical care, and because they are observational, all patients receiving treatment can be 
included, irrespective of dosage. This brings sound external validity as ‘registry enrolled patients’ 
generally have an increased baseline risk than ‘RCT enrolled patients’. Further, the research period 
of registries is longer than RCTs, allowing long-term follow up of new approved therapies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 Clinical Observation 
3.3.2.1 Case Example – Clinical Trials 
The Cryopyrin-associated periodic syndrome (CAPS) registry is an example of a registry being used in place 
of a RCT for post-marketing purposes (Tilson et al, 2013). CAPS are a group of rare, hereditary 
autoinflammatory diseases. Symptoms, such as fever and systemic inflammation, present as recurrent 
episodes throughout the entire lifetime of the patient, and can become life-threatening. Canakinumab, a 
monoclonal IL-1-β antibody, is an approved treatment for CAPS patients. Like all RDs, the clinical 
development of Canakinumab recruited a very limited number of patients; therefore, post-approval 
monitoring to assess the short and long-term safety and efficacy was critical. The CAPS registry was 
established in 2009 as an online, observational registry with the aim of gathering information regarding the 
natural history of disease as well as the beneficial and adverse effects of treatment over a 5-year period.  
With no exclusion criteria, protocol-mandated visits, or procedures, physicians successfully collected data 
from 241 CAPS patients over 5 years during routine visits to clinic, significantly more than the original drug 
approved dossier of 78 CAPS patients over a 3.5-year period. An update of the safety profile of 
Canakinumab in 2013-2014 reported no new or unexpected safety concerns, with no loss of efficacy of the 
drug (Hoffman et al, 2016). Moreover, the findings were consistent with the previous clinical trials.  
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3.4.1 Epidemiology and Studies of Phenotype 
This review found that registries both with and without BBs impacted on RD research outcomes with 
regards to epidemiological studies, providing further insight into the disease. This review found that 
RD registries can gain insights into the incidence/prevalence of the disorder and survival, natural 
history, relationships between genotype and phenotype, and understand the burden of disease. 
Captured epidemiological data in this review included age, characterisation of symptoms, gender 
distribution, ethnic background, provision of care at different sites, diagnosis of patient, and data 
pertaining specifically to the disease of interest (Fascnacht, Tolsa, & Beghetti, 2007; Tilson et al., 
2013; Evangelista et al., 2016; Hilbert et al., 2012; Rodger et al., 2013; Brandenburg et al., 2016; 
Fisher et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.1.1 Case Example –Epidemiology and Studies of Phenotype 
TREAT-NMD, a registry network for neuromuscular diseases, provides evidence of how RD initiatives can 
impact on genetic epidemiological outcomes. Duchenne Muscular Dystrophy (DMD) is a progressive 
neuromuscular disease caused by mutations in the DMD gene, leading to a depletion of dystrophin within 
the muscle (Hoffman et al, 2012). The TREAT-NMD DMD global database is thought to be the world’s largest 
cohort of DMD mutations, containing over 7,000 mutations (Bladen et al, 2015). The initiative collects and 
compares information regarding DMD mutations (such as location of mutation). Gaining an insight into the 
type and frequency of mutations that cause DMD is invaluable for genetic diagnosis, basic science, clinical 
care, and personalised/targeted therapy (Bladen et al, 2015).  
Analysis of the TREAT-NMD DMD Global database showed that, regardless of geographical location, the 
most prevalent mutation are large deletions (68%) with exon 45 being the most common deletion (reported 
316 times). Of the 7,149 mutations, 5,684 (80%) are insertion/deletion (INDELS) mutations, and 1,445 (20%) 
are small point mutations. Half of all small point mutations (10% of total mutations) are nonsense 
mutations: point mutations that lead to a premature ‘stop’ codon being introduced into the amino acid 
sequence. This usually results in a non-functional protein, causing disease. A potential DMD therapy that has 
achieved marketing approval is nonsense stop codon read-through therapy (Welch et al, 2007). This 
treatment selectively induces ribosomal read-through of premature stop codons but not normal stop 
codons. The database identified 317 mutations (4%) with a premature TGA stop codon, 215 (3%) with a TAG 
stop codon, and 194 (3%) with a TAA stop codon, that would potentially benefit from this available therapy. 
Another therapy for DMD is exon-skipping technology (van Ommen and Aartsma-Rus, 2013).  Exon-skipping 
takes advantage of the fact that internally deleted dystrophins can be partly functional (van Ommen and 
Aartsma-Rus, 2013). Mutations were identified in the database that would potentially benefit from exon-
skipping, such as skipping of exon 51 (14% of all mutations) and 53 (10%). This example highlights how 
registries can impact on epidemiological outcomes and can assist in identifying patients who may benefit 
from already existing therapies. 
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3.4.2 Natural History of Disease  
Registries both with and without BB impacted on the natural history of disease by gaining insight 
into the natural course of disease. This is important as it assists researchers in developing preventive 
strategies from a general framework. Registries in this review observed factors that accelerated or 
slowed development of disease, understood better the resultant disease sequalae, and made new 
findings regarding disease progression.  
 
 
 
 
 
 
 
 
 
 
 
3.4.3 Diagnosis, Survival Rates, Patient Outcomes  
Registries with- and without- BBs impacted on clinical observation outcomes in regards to diagnosis, 
survival rates and patient outcomes. Registries in this review observed long delays between 
symptom onset and diagnosis, with multiple consults by specialists observed prior to gaining a 
confirmed diagnosis. Registries with BBs had the capacity to store samples for clinicians from 
undiagnosed patients with the view at future diagnosis, providing retrospective diagnoses. Survival 
rates could be established for various diseases, as well as outcomes at follow-ups in this review.  
 
 
 
3.4.2.1 Case Example – Natural History of Disease 
A novel finding regarding the natural history of disease was uncovered through the German Calciphylaxis 
registry (Brandenburg et al, 2016). Calciphylaxis is a very RD that carries a high mortality. It is frequently 
found in patients with end-stage renal disease on dialysis, and manifests as severe skin ulcerations and 
calcification of cutaneous arterioles (Brandenburg et al, 2016). The German registry was established to 
identify potential risk factors for disease, clinical practice methods, and biomarker analysis. This was 
achieved by collecting clinical information as well as blood samples, stored in the registry’s BB. Whilst the 
registry validated previous reports that end-stage renal disease appears to predispose patients to 
Calciphylaxis, the novel finding came from the laboratory testing on patient samples, which measured serum 
calcium, phosphorus and parathyroid hormone levels. The biochemistry results found that parathyroid 
hormone levels in Calciphylaxis patients were unexpectedly low. The authors recommended that future 
studies need to explore the trend and time course of these biochemistry markers (calcium, phosphorus, and 
parathyroid hormone) in the months leading up to Calciphylaxis development.  
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3.5 Clinical Treatment 
3.5.1 Diagnostics  
This review found that RD registries contributed to observing which participating centres lacked 
appropriate diagnostic criteria, whilst also supporting the development of new diagnostic testing 
methodologies.  
 
 
 
 
 
 
 
3.5.2 Guidelines for Treatment  
Registries both with and without BB impact on clinical treatment. Rare diseases commonly lack 
evidence-based treatment protocols, attributed to the low number of patients seen at any one 
centre. Registries in this review facilitated multi-centre collaboration, which in turn led to 
discussions among experts regarding treatment protocols and best practice. This contributed to the 
management of disease, impacting on patient outcomes.  
 
 
3.4.3.1 Case Example – Diagnosis, Survival Rates, Patient Outcomes 
The International Collaborative Gaucher Group registry provides an example of how registries can 
establish survival rates (Mistry et al, 2015). Gaucher disease is a rare, heterogeneous inborn error of 
metabolism with three main phenotypic categories. Among its other manifestations, Gaucher disease type 
1 is characterised by splenomegaly. A sub-study from the registry established that Gaucher disease type 1 
has a 9-year reduced life-expectancy compared to that of the normal population, possibly as a result of the 
impact of splenectomy (Mistry et al, 2015).  
 
3.5.1.1 Case Example – Diagnostics 
The EuroBioBank (EBB), the first BB network in Europe (and also a partner of the TNGB) collects, processes 
and stores biological samples (such as DNA and tissue) for provision to the RD scientific community (Mora 
et al, 2013). One partner of the EBB, known as the Instituto Nazionale Neurologico Carlo Besta, provides 
samples for new diagnostic tests when they become available. This provides another utility of a BB by way 
of supporting diagnostic development.  
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3.5.3 Treatment Evaluation 
Registries both with and without BBs impacted on treatment evaluation for RD. Existing therapies 
and surgical interventions, and their outcomes, were observed. This led to a greater understanding 
of which therapies affected disease course.  
 
 
 
 
 
 
\ 
 
3.5.2.1 Case Example - Guidelines for Treatment 
The Juvenile Myositis registry is one such example of how registries can impact on treatment 
guidelines (Martin et al, 2011). Juvenile Myositis is a group of rare, chronic inflammatory disorders in 
childhood, affecting muscles and other organs. This disorder is associated with a high level of 
morbidity and mortality. There is a severe lack of evidence-based treatments for Juvenile Myositis, 
with almost no level-1 evidence from trials regarding therapies, and little is known about the 
underlying mechanisms of the disease. Through collaboration with multiple centres, the registry 
facilitated discussion among experts regarding current treatments. It was observed that early 
management of Juvenile Myositis improved treatment outcomes, whereas a delay in treatment led to 
poorer outcomes. The outcome was a shift in practice; specifically, widespread adoption of earlier and 
more aggressive treatments. In addition, the assessment process for children with Juvenile Myositis 
changed in participating centres as a result of the registry. The registry employed the Childhood 
Myositis Assessment Scale, a tool previously validated to assess muscle function, as part of their data 
collection process. As a result, this assessment tool has since gained widespread use throughout the 
UK for management of Juvenile Myositis, and is now part of routine clinical practice in participating 
centres.  The registry is currently working on establishing treatment protocols for this disease.  
 
3.5.3.1 Case Example – Treatment Evaluation 
The Swiss Registry for Pulmonary Arterial Hypertension (PAH) collects information pertaining to 
paediatric PAH, a rare condition leading to high blood pressure in the lungs of affected children 
(Fasnacht et al, 2007). PAH has a poor prognosis if left untreated. Information regarding treatment 
outcomes for paediatric PAH are scarce. The Swiss registry evaluated treatment outcomes from 23 
paediatric PAH patients, with a median follow-up of 3.47 years. Therapies included Bosentan, 
Sildenafil, and inhaled Iloprost, administered in isolation or in combination. Whilst the treatments 
were heterogeneous, it was found that the majority of PAH patients achieved stabilisation of their 
condition under these current available therapies.  Further, some patients demonstrated an 
increased exercise tolerance with improved functional status on these therapies. The authors 
highlighted the usefulness of such a registry for gathering vital information on therapies for RD.  
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3.6 Facilitators 
3.6.1 Benefits to Stakeholders 
Registries with and without BBs benefit stakeholders. This review found that participants, patient 
advocacy groups, researchers, and clinicians all benefited from participation in RD registries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6.2 Collaborations  
This review found collaborations between registries and various stakeholders are vital to the success 
of the registries aims and objectives. The registries collaborated with numerous groups including 
hospital sites, academic centres, clinicians, patients, scientists, patient advocacy groups, 
pharmaceutical and diagnostic industries, societies, foundations and other registries. Collaboration 
was local, regional, national, or international. Collaborative approaches facilitated review and 
discussion of treatment protocols, improving treatment outcomes. Continuous engagement assisted 
3.6.1.1 Case Example – Benefits to Stakeholders 
Eyegene, a registry and BB dedicated to phenotyping and genotyping rare inherited eye diseases, 
provides a comprehensive example of how registries benefit numerous stakeholders (Blain et al, 2013). 
Established by the National Eye Institute, Eyegene’s reach encompasses the USA and Canada. Patients 
diagnosed with genetic eye diseases are clinically characterised, and have their DNA stored in a BB. 
Research is then conducted into the underlying pathogenesis of disease. Patients participating in the 
initiative benefit by being involved in current research which may elucidate the genetic cause of their 
condition. Eyegene found that patients chose to participate in research studies even when they knew the 
genetic cause of their disease. Patient support groups presented clinically characterised, previously 
genotyped individuals to Eyegene for participation, benefiting by expanding their access to research. 
Clinicians referring their patients to Eyegene benefited by receiving a molecular diagnosis of their patient, 
confirming the initial clinical diagnosis. Eyegene has provided diagnostic results to over 55% of 
participants enrolled, and has over 4,400 samples stored with Eyegene. This may help to better monitor 
and manage respective inherited eye conditions. Furthermore, through Eyegene, both clinicians and 
patients gain access to information regarding the availability of clinical trials. Finally, the scientific 
community benefited from Eyegene by accessing clinical data linked to biological samples, which 
progressed research in the field of inherited eye diseases. For example, Eyegene initially tested 20 genes 
over 9 disease categories, but now tests more than 100 genes over 35 categories, the result of gene 
discovery through the network.  
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clinicians with follow-up, with more complete data being reported. International collaborations 
increased patient cohort size, leading to increased interest from industry.  
 
 
 
 
 
 
 
 
 
 
3.6.3 Engagement 
Engagement strategies reported by the registries included the international nature of the registry, 
ongoing communication between the registry and participating sites, collaboration, methods of 
recruitment, using data collection forms in place of clinical notes to ease the burden of form filling, 
inclusion of any interested clinics to increase participant numbers, and equal sharing of funding 
leading to continuation of data collection even when the funding ceased.  
 
 
 
 
 
 
 
 
 
3.6.2.1 Case Example – Collaborations 
The approval of Strimvelis required extensive collaboration between numerous stakeholders, 
establishing a new paradigm for RD research. Cooperation was facilitated between academia, not-
for-profit organisations, and the pharmaceutical/biotech industry, evidencing how this transparent 
collaboration overcame the numerous barriers associated with drug development for RDs (Aiuti et 
al, 2017).  The combined efforts that accelerated the commercialisation of Strimvelis resulted in a 
“turning point for the field” and has charted a “clear path” for similar gene therapy developments 
(Aiuti et al., 2017). The success of the methods developed for the success of Strimvelis extends 
beyond the obvious benefits to the patient, with the strategies employed for quality assessment, 
manufacturing, administration of the drug in the clinical setting, and policies for drug cost and 
reimbursement serving as a precedent for future efforts. (Aiuti et al, 2017).  
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3.6.4 Recruitment 
Registries in this review employed novel methods for recruitment of RD patients. This lateral 
thinking is especially important given the small number of patients scattered geographically.  
 
 
3.6.3.1 Case Example – Engagement 
The TNGB attributed 4 major strengths to the success of their national network (Filacomo et al, 
2013). Firstly, the Coordination Office, managed by the Coordinator of the entire network, 
ensured harmonisation and standardisation of all operating procedures (including collection, 
processing, and storage of samples and data) throughout the BB. The TNGB reported that 
maintaining interoperability throughout the BB has prevented siloing and disorganisation from 
individual efforts. Secondly, a unique collaborative model between the TNGB and various patient 
support groups for RD in Italy was established. Patient support groups have always had 
representation on the advisory board since the inception of the network, providing insight and 
feedback on governance issues such as ethics, consent, and confidentiality. In addition to this 
role, a “coordinator emeritus” was appointed to support the coordinator by the TNGB to liaise 
between the patient support groups in Uniamo, an Italian federation of over 100 RD associations. 
The coordinator emeritus initiated meetings and workshops with the aim of fostering trust and 
interest among patients and their families regarding the concept of the BB, and how it can 
provide a resource for future RD research. The TNGB reported that there is a significant increase 
of interest in the BB, and that patient and family involvement have been vital for both reaching a 
critical mass of biological samples, as well as taking the patients’ needs and concerns into 
account. Thirdly, the TNGB used a novel approach in dedicating a specific patient support group 
to one of the BB in the network. Termed a “framework agreement” and there are now six such 
agreements in place. Within the framework, patient groups can promote and cofound research 
projects with the BB they are partnered with, with two projects now developed as a result of this 
agreement. Lastly, the TNGB attributes another strength to its success through its online 
catalogue. The “virtual biobank” lists all samples stored within the BB network online, making 
some 75,900 samples visible to the international scientific community. 
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3.6.5 Pro-active Marketing  
A strategic, targeted, pro-active marketing approach demonstrated how even a single BB site can 
have a significant impact on RD research outcomes, and can contribute to key research studies 
throughout the world.   
 
 
 
 
 
 
 
 
 
 
3.6.4.1 Case Example – Recruitment 
The Canadian Neuromuscular Disease Registry (CNDR) is a national registry established in 2011 
(Korngut et al, 2013). The CNDR was established to bridge the gaps of knowledge for rare, 
neuromuscular diseases in Canada. The registry utilised a novel recruitment approach to “cast the 
net” as far as possible and reach patients affected by neuromuscular disease. Blended 
recruitment, the term given to this model, offers several methods for recruiting patients. In 
addition to the traditional approach of clinicians enrolling patients during routine visits to clinic, 
the CNDR also offers direct self-registration through the registries main office, with the option of 
patients registering themselves through the CNDR public website, connecting interested patients 
with CNDR staff at head office. Blended recruitment offers a novel approach to recruitment, 
enabling both clinicians and patients to recruit through several means. As a result, the CNDR 
recruited 253 Duchenne and Becker Muscular Dystrophy patients, 161 myotonic dystrophy 
patients, and 71 ALS patients. Enrolment extended to 12 provinces and territories, confirming the 
feasibility and efficacy of blended recruitment for RD registries. 
 
3.6.5.1 Case Example – Pro-active Marketing 
The Tumour Bank at the Children’s Hospital Westmead (TB-CHW) is a single site BB with a 
research focus on rare paediatric malignancies (Zhou & Catchpoole, 2015). They have been pro-
active when forming collaborations. The TB-CHW actively sought out international, leading world 
experts whose research and results would most likely lead to a greater understanding of 
childhood cancer through the addition of TB-CHW samples. This novel approach has facilitated 
84 research projects around the world, resulting in over 40 genomic-based research publications 
(Zhou & Catchpoole, 2015). Interestingly, 76% of  research publications were from collaborations 
between international researchers, underscoring the importance of a single site RD registry with 
a BB to the international research community (Zhou & Catchpoole, 2015). 
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3.7 Barriers 
3.7.1 Challenges 
Challenges reported by the registries in this review included incomplete data sets, data accuracy 
(error), study design, lack of follow-up, lack of standardisation, and funding restrictions. Another 
challenge was the ability to reach, recruit and capture all patient cases. It was also found that BBs 
that cover a broad range of diseases are limited in their ability to reach a critical mass for a particular 
disease diagnosis or category.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.7.1.1 Case Example – Challenges 
 
Whilst the advent of next-generation sequencing (NGS) provides unparalleled opportunities for 
RD research, the TNGB found limitations when implementing this technology due to legal and 
ethical concerns (Filacomo et al, 2013). It was noted their current informed consent was 
restricted to that patient’s particular disease, and lacked the necessary broad consent to 
implement NGS. Moreover, governing the sheer volume of information generated by NGS 
required additional considerations. This was especially so when managing “incidental findings”. 
In response, the TNGB collaborated with experts in order to accelerate national regulations for 
BB.  
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Theme Category Identified in 
RD registries 
linked to BB 
Identified in RD 
registries without 
BB 
Basic Science Omics    
 Biomarker development    
 Subcohort identification    
 Epidemiology     
Translational 
science 
Increased number of research 
projects 
    
 Randomised controlled trials     
 Biospecimen contribution to 
studies 
   
Clinical 
observation 
Diagnosis/survival rate     
 Natural history of disease     
Clinical treatment Diagnostics      
 Guidelines for treatment     
 Treatment evaluation     
Facilitators Benefits to stakeholders     
 Collaborations     
 Strengths     
Barriers Limitations     
 Other      
Study quality Research period     
 Recruited participants     
 Samples collected    
 Research projects     
 Publications     
 Confidentiality     
 
Table 3. Synthesized Themes and Categories identified in RD registries with and without BB 
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4 Discussion 
This systematic review sought to identify the impact of BBs on research outcomes in registries for 
RDs. We analysed and compared the research endpoints of two specific populations: registries with 
BBs and registries without BBs. Findings were grouped into themes: basic science, translational 
science, clinical observation, clinical treatment, study quality, and facilitators and barriers. We 
observed key differences among the research endpoint variables between registries with and 
without BBs. Most notably, registries with BBs included basic science as a research endpoint, 
observed to lie exclusively within the domain of registries with BBs. This review found that the 
inclusion of basic science as a research endpoint variable in registries has significant and far-reaching 
consequences by way of facilitating translational research, leading to the discovery and 
development of new treatments and therapies for RDs.  
RD registries are often the only resource for the disease of interest (Gliklich & Dreyer, 2010). 
Registries are gradually being recognised as a global priority in RD research; the essential “building 
blocks” for RD epidemiological, clinical research, and post-marketing studies (Eurordis, 2011). In this 
review, RD registries without BBs facilitated epidemiological research, clinical research, and post-
marketing surveillance studies. Furthermore, registries were found to not only replace clinical trials, 
but to offer several benefits to them, including no restrictions in cohort size and no dictated 
treatment regimens. This provided sound external validity, with patients being observed over longer 
periods of time in “real-world” settings, an important finding. Rare disease registries led to a greater 
understanding of the natural history of disease, consensus-driven treatment protocols, and 
ultimately improved patient outcomes. 
An important consideration is that some registries collect the results of genetic testing and therefore 
store phenotype/genotype data, but not biological samples. This does not constitute a BB per se, as 
the registry cannot conduct basic research. For example, the Australian Cystic Fibrosis registry 
collected phenotypic/genotypic data from 3087 patients, allowing stratified genetic analysis in 91.7% 
of all registry members (Ahem et al, 2015). It is also important to note that clinical quality registries 
are set up specifically not to do research. 
Despite these benefits, registries without BBs in this review were restricted in their smaller capacity 
to contribute to basic research, attributable to a lack of infrastructure required to conduct the 
necessary laboratory-based investigations. Further, basic research studies are made possible 
through the availability of human biological specimens (Zhou & Catchpoole, 2015). It is only through 
the collection and investigation of human biological samples matched to clinical data that novel 
diagnostic, prognostic, and therapeutic avenues can be developed (Fisher et al, 2013). This is 
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particularly important considering drug innovation for RD has, in recent years, become progressively 
focused on Omics studies, with the identification of molecular targets leading to the development of 
new therapies (Gahl, 2014). 
Registries linked to BBs contributed more to basic research. Findings included novel Omics 
discoveries, biomarker development (screening, validation, replication and clinical trial), gene 
identification, elucidation of biological and cellular pathways, models for drug-screening, and 
therapeutic discoveries. As 80% of RD have a genetic component, genomic analyses may assist in not 
only obtaining a correct diagnosis but also contribute to RD genomic research (Chong et al, 2015). 
Furthermore, conducting genomics research can contribute to our knowledge of gene regulation and 
function, as well as gaining an understanding of the underlying biological pathways of disease that 
can then be translated into developing new therapies (Chong et al, 2015).  
The development of new therapies for RDs is critically significant as they can be of a life-saving 
nature. This is best demonstrated by Strimvelis, the first ex vivo stem-cell gene-therapy for children 
to gain marketing approval anywhere in the world (Aiuti et al, 2017).  In spite of the ground-breaking 
success of Strimvelis, Fondazione Telethon remains committed to its original focus of basic research, 
stating “basic science is the foundation on which future treatments will be developed” (Monaco & 
Faccio, 2017). This provides a powerful message to RD stakeholders; scientists must first understand 
the pathways of disease before they can develop appropriate interventions. 
The premise that basic science is the key component in RD registries for the discovery and 
development of new therapies is consistent with statements from; the Eurordis position paper on 
research priorities for rare diseases 2014-2020, which states “basic research is the prerequisite of 
any therapeutic advance and of any new public health decision”; a recent joint declaration by the 
European Organisation for Rare Diseases (EURORDIS), the National Organization for Rare Disorders 
(NORD) and the Canadian Organization for Rare Disorders (CORD) 10 key principles for RD patient 
registries, which states “Rare Disease Patient Registries data should be linked with corresponding 
biobank data”, adding that RD registries provide the key infrastructure for translating basic research 
into new therapies; and the WA Rare Diseases Strategic Framework 2015-2018, which recognises 
patient registries as a priority for research, supporting the development and integration of patient 
registries with BBs  (Eurordis, 2011; Eurordis, 2012; Department of Health, 2015).  
Whilst linkage of BBs to registries have been identified as important for translational research, in 
reality, BB are expensive (Hoffman et al, 2013). A recent survey of 456 BB found that 71% of 
respondants interviewed were concerned about funding (Cadigan et al, 2013). The associated costs 
of BB vary dependent on the size and structure of the BB. For example, a small resource involving a 
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single freezer in a university laboratory will have a vastly different structure (and hence, costs) to a 
national BB collecting samples from multiple sites (Vaught et al, 2010).  Methods to reduce BB costs 
was suggested through the implementation of a cost-accounting tool for BB, specifically, two 
mathematical models designed to address production costs and request costs (Gonzalez-Sanchez et 
al, 2014). Consideration of multiple factors including numbers and types of samples stored, size of 
BB, concentration strategies in BB networks, as well as demand of researchers and international 
strategies of the BB may serve to decrease associated costs and improve financial sustainability of 
the BB (Gonzalaz-Sanchez et al, 2014). Implementing such a tool may assist to reduce the 
costs/barriers for RD registries wanting to incorporate a BB into their resource. However, this must 
be accompanied by appropriate levels of commitment from major national and international funding 
bodies. 
In addition to these findings, this review found several factors which, when utilised, served to 
strengthen the success of RD registries.  
The collaborative effort of Strimvelis provided a new paradigm for RD research. Strimvelis required 
open coordination and collaboration between academic institutions, bio-tech companies, the 
pharmaceutical industry, and not-for-profit organisations in order to overcome the numerous and 
often insurmountable obstacles in developing a new therapy for RD (Auiti et al, 2017).  
The strengths of the TNGB included appointing a Coordinating Officer to lead the project to develop 
standardisation of data sets, operating procedures and policies, which enabled harmonisation and 
standardisation of all participating sites. A Coordinator Emeritus supported the Coordinating Officer 
by liaising with patient support groups, which increased patient interest and participation in the 
resource. The TNGB provided an effective model of collaboration between disease-specific BB and 
patient organisations, the importance of which must be underscored (Baldo et al, 2016). Patient 
organisation interest in the disease-specific BB led to their want to donate biological specimens. As a 
result, 13 written agreements were formalised. The agreements allowed the formation of RD genetic 
samples and their clinical data to be available to the scientific community (Baldo et al, 2016).  
The TNGB provided visibility of the resource through their website and “virtual biobank” online 
catalogue. This is similar to the RD-Connect sample catalogue, which provides a detailed inventory of 
available biological samples in participating BB. These online catalogues allow researchers to see, 
select and apply to access the biological samples of interest (Gianotti et al, 2018). RD-Connect have 
also developed the “RD-Connect Registry and Biobank Finder”, a unique tool to assist RD researchers 
find BB and registries. The finder currently has data for 222 registries and 21 BB (Giantotti et al, 
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2018). These catalogues are of great importance as they facilitate RD research on an international 
scale, making samples and data easier to located and access. 
Another finding was the novel approach of “blended recruitment”. Blended recruitment “casts the 
net” as wide as possible to recruit the maximum number of patients. This approach utilises several 
recruitment methods including direct enrolment of the patient by the clinician, as well as indirect 
enrolment by the patient themselves through head office of the registry or through the study’s 
website. Through this unique strategy, the CNDR could recruit more patients than would have 
otherwise been possible through traditional means. The TB-CHW provided evidence of how a single 
site BB can still have a significant impact on contributing to international research for RD, attributed 
to its pro-active, targeted marketing of available samples to leading experts. Another important 
finding was the recognition of the need for broad consent to accommodate advancements in NGS 
technologies. A review of the ethics process was required by the TNGB, with broad consent requiring 
consideration in the management of large volumes of data, return of results, and incidental findings.  
A limitation of this study is that our chosen search terms used to locate all necessary and relevant RD 
registries and associated BBs may have led to a “filed-effect” of articles, precluding other valuable 
studies from our review by default.  Meanwhile a scenario of BBs without registry should also be 
considered to more fully articulate the role of BBs. Whilst we have done our best to conduct a 
comprehensive and exhaustive search for all RD registries and BBs, we acknowledge there may be 
other RD registries and BB initiatives that were missed, attributed to the fact that they were outside 
our search term criteria.  
Whilst this review provides unequivocal evidence of the impact BBs linked to registries have for RDs, 
countries, like Australia, are yet to act to remedy the situation. This is despite a call to action from 
peak bodies and the strong enthusiasm from clinicians, researchers, and patients themselves. 
Indeed, this enthusiasm is not enough to effect meaningful change, with real support from the 
government urgently needed to make any real progress (Lacaze et al, 2017). Whilst there are 
individual research efforts throughout the country, the number of RD registries in Australia is few 
and still largely unknown. It is known individual research efforts can lead to siloing of information 
and disorganisation. Further, there is no central, coordinated effort to collect, store, and distribute 
biological samples for the scientific community, nor do efforts exist to link such a resource to the 
clinical data stored in registries. Moreover, there is a general lack of funding and interest to change 
the current climate of RDs. However, the lack of basic research activity for RDs in countries such as 
Australia is itself a unique opportunity as there is the ability to begin a national approach from a 
“clean slate”. The concept of establishing a National RD Biobank Network for Australia has been 
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supported in the WA RD strategic framework (Department of Health, 2015). The validity and 
feasibility of such an initiative has been successfully demonstrated by similar models in other 
countries. For example, the Telethon Network of Genetic Biobanks has linked 11 individual BB 
throughout Italy, storing in excess of 100,000 biological samples for more than 950 rare genetic 
diseases. Australia needs a dedicated and passionate group of researchers to form a steering 
committee and drive a similar venture, through the guidance of existing national RD and BB experts. 
Criteria for inclusion could be for the disease to a) be confirmed as rare according to Orphanet 
criteria, b) have a genetic component, and c) to collaborate with an existing international registry. 
This strategy will enable access to existing protocols, provide support, and bring enthusiastic 
researchers together.  Recruitment could be through referral from either the patient’s specialist or 
General Practitioner. Data collection would depend on each international registry/BB. One possible 
model for sample collection would be, in the first instance, to form agreements with existing BB in 
each state, storing samples according to the expertise of that BB. For example, a BB specialising in 
musculoskeletal conditions could store the nation’s samples for rare genetic musculoskeletal 
diseases. Establishing minimum sample numbers (for example, agreeing to store a maximum of 200 
samples in each BB) could be an economic strategy for the network, as BB facilities may be able to 
provide a few shelves of a freezer at low cost, or even in kind. It is only once RD registries are linked 
to BBs we will have the appropriate resources required for the effective translation of basic research 
into clinical practice. This has the capacity to lead to new diagnostic tools and therapies, ultimately 
improving patient outcomes and alleviating the significant burden associated with RD for clinicians, 
hospitals, society, and most importantly, the patients and their families.    
4.1 RECOMMENDATIONS:   
The following evidence-based recommendations are derived from this systematic review and align 
with the WA Rare Disease Strategic Framework 2015-2018, and the joint declaration of 10 key 
principles for RD patient registries by the European Organisation for Rare Diseases (EURORDIS), the 
National Organization for Rare Disorders (NORD) and the Canadian Organization for Rare Disorders 
(CORD).  
1. Established (RD) disease-specific registries without BBs should be identified, with an 
agreement reached to include Omics investigations as a research endpoint20 
2. Existing BB infrastructure that specialises in the registries disease of interest should be 
identified and linked to the RD registry with agreements made to store samples24 
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3. A coordination office should be established in order to govern the project and achieve 
harmonisation throughout the network at national or international level19 
4. A steering group should be created and consist of representatives from the following 
stakeholders; patients, patient support groups, clinicians, and researchers19 
5. Engagement strategies should be employed by the registries and include ongoing 
communication between the registry and participating sites34 
6. The network should develop a generic patient information sheet with a single “broad 
consent” to encompass every RD, compliant with but streamlining the human research 
ethics processes29 
7. The network should adopt a “blended recruitment” approach, ensuring the largest possible 
geographical reach, with direct (patient) or indirect (clinician) enrolment34 
8. Data collection forms should be used in place of clinical notes where possible to ease the 
burden of form filling and increase compliance29 
9. The network should have a website and online catalogue of all available samples for the RD 
scientific community19   
10. It is recommended the registries adopt a pro-active, targeted marketing approach, liaising 
with national and international leading experts14 
11. Equal sharing of funding for each site should be considered as this leads to continuation of 
data collection even when the funding ceased29 
 
4.2 Limitations 
 
A limitation of this study is that our chosen search terms used to locate all necessary and relevant RD 
registries and associated BBs may have precluded other valuable studies from our review by default. 
In addition, there is potential that additional databases have been newly established due to the 
study of RD growing in momentum. There is also the limitation of relying on published literature 
from which we drew our findings. It should be acknowledged that there are existing registries that 
are active but do not publish, and that should be taken into account when interpreting our results. 
A second limitation in our study was that all resources under analysis were classified as registries. 
Whilst all resources collected data, we did not consider the different levels of registries. As a result, 
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databases with minimum, basic, and common data sets were classified as registries and compared 
with epidemiological, clinical care, and comprehensive registries. In this study, a patient registry was 
defined as an organized system that uses observational study methods to collect uniform data 
(clinical and other) to evaluate specified outcomes for a population defined by a particular disease, 
condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy 
purposes. A registry database is a file (or files) derived from the registry (Glickich at al, 2010). Patient 
registries represent a useful tool for a number of purposes. Their ideal use and their role in evidence 
development, design, operations, and evaluation resemble but differ from clinical trials in a number 
of substantive ways, and therefore they should not be evaluated with the same constructs. That 
said, our coming updated meta-analysis will consider and compare registries with similar study 
design and data sets, which will strengthen the overall assumption of such analyses.  
Another limitation of this study was not considering the possibility that biobanks may not be 
associated to registries. Although this study is centred around the comparison between registries 
associated or not associated to biobanks, the Biobank which is not associated to registry should not 
be neglected. Our coming updated meta-analysis will focus on this scenario as one additional 
category. 
4.3 Future directions 
The findings of this systematic review highlights the importance of annexing BB to established RD 
registries with regards to providing a valuable resource for future omics research. As highlighted in 
the literature review at the start of this thesis, establishing a BB takes considerable planning, 
coordingation, effort, resources, and time. Despite this, our findings indicate that BB are vital for 
progressing omics-based research.  
 
5 Overall summary 
 
5.1  Findings  
 
It was shown in the systematic review that registries without BBs had the capacity to uncover the 
natural history of disease, develop best practice, replace clinical trials, and improve patient 
outcomes, but they were limited in their capacity to conduct basic research. Registries, when 
annexed to BBs, had the key infrastructure required to make novel Omics discoveries, identify and 
validate biomarkers, uncover novel genes, and develop new therapeutic strategies. The role of basic 
research in RD research is vital; scientists must first understand the pathways of disease before they 
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can develop appropriate interventions. This is especially important considering drug innovation for 
RD has, in recent years, become progressively focused on Omics studies. It is only once RD registries 
are linked to BBs we will have the appropriate resources required for the effective translation of 
basic research into clinical practice.  
The systematic review also found that registries benefited numerous stakeholders. Broad consent, 
harmonisation and standardisation of procedures, blended recruitment, and pro-active marketing 
aided in the success of research outcomes.  
5.2 Strengths  
 
A strength of this study was the methodology used. Meta-aggregation allowed us to qualitatively 
identify that registries without BBs were limited in their capacity to conduct basic research. Through 
categorizing our findings based on similarities of meaning, we were able to synthesize groups of 
findings using a clear evidence base. We found that that linkage of RD registries with BBs provides 
researchers with the necessary resources required for basic science investigations. Basic science is a 
vital pre-requisite for translational medicine, and has the capacity to lead to new diagnostic tools 
and therapies in the clinical setting. RD research is important not only for rare diseases, but also for 
also common diseases, e.g., research of low-density lipoprotein (LDL)-receptors in the RD known as 
familial hypercholesterolemia led to the discovery of statins, a drug therapy that is now used 
routinely to prevent heart disease. Linkage of BBs to RD registries are essential for the discovery of 
new diagnostic tools and therapies, and ultimately improves patient outcomes and alleviates the 
significant burden associated with RD for clinicians, hospitals, society, and most importantly, the 
patients and their families.    
 
5.3 Implications for Future Research 
 
From this Master’s thesis research findings, a set of recommendations for future RD research were 
developed. These recommendations can be immediately applied to both practice and policy. 
Employing these recommendations in the future will be an especially important factor in 
accelerating RD research findings, particularly with regards to Omics research. Adopting these 
recommendations will be a useful tool for designing an effective pathway for moving research 
findings along the translational research continuum at optimal speed, and translating basic science 
findings into new therapeutics. Considering the development of drug therapies on average is 10 
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years (from bench to bedside), adopting strategies which can accelerate this pathway is a clear 
benefit for all involved in RD, particularly the patients and their families.  
 
Following these recommendations, a clear and practical next step would be to annex an established 
BB to an established international RD registry. For example, the Growing Spine Study Group (GSSG) 
is an international, disease- specific RD registry that collects clinical data from Early Onset Scoliosis 
(EOS) from 30 sites in 9 countries throughout the world. The GSSG has now commenced sample 
collection, storing samples centrally in an established BB in each country. For example, in North 
America, samples are collected, transported, and stored in a BB at Texas Scottish Rite Hospital; a 
participating site of the GSSG. This offers several advantages for accelerating research outcomes. 
The first is that clinical data is already being collected, and would complement sample collection 
well. This is an important consideration as samples must have matched clinical data to add real value 
in determining genotypic/phenotypic relationships. The second is that there are already strong 
advocates in the registry for the disease, namely, participating clinicians, researchers, and patients. 
The third is the minimal cost associated with collecting samples through this pathway. Samples 
numbers collected for EOS are small, and can be stored in one section of a freezer. This model has 
the potential to accelerate research outcomes by minimising the burden of cost, time, and effort in 
setting up such a resource.  
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